Navigation Links
PacificGMP and Actinium Pharmaceuticals Announce Agreements for cGMP Antibody Manufacturing and Stability Testing
Date:11/20/2008

SAN DIEGO, Nov. 20 /PRNewswire/ -- PacificGMP, the leader in single-use bioprocessing for development and manufacturing, has entered into a cGMP contract manufacturing agreement with Actinium Pharmaceuticals, a biopharmaceutical company developing new targeted therapies for cancer. Under the agreement, PacificGMP will manufacture and perform fill/finish of Actinium's HuM195 monoclonal antibody for a Phase I/II clinical trial. A stability study of the final product will also be conducted. HuM195 is a monoclonal antibody that is currently being tested in a Phase I clinical trial to treat acute myeloid leukemia.

"We are delighted to establish a partnership with Actinium Pharmaceuticals and initiate cGMP production for their new Phase I/II clinical trial," said Leigh N. Pierce, President of PacificGMP. "With our strong track record of monoclonal antibody production, this project is a perfect fit for our companies and we look forward to efficiently providing Actinium with a high quality GMP product."

"We are excited to work with PacificGMP, a company with demonstrated expertise in biopharmaceutical manufacturing. Their capabilities and ability to quickly step into this role are precisely what Actinium was looking for in a manufacturing partner," said Howard Wachtler, President and Chief Executive Officer for Actinium.

About PacificGMP

PacificGMP is a contract manufacturer and industry leader in single-use technology for development and manufacturing of biologics. Single-use technology eliminates the risk of cross-contamination, has fewer system requirements and significantly reduces the time required to initiate production. Benefits to clients include rapid project turnaround and the most cost effective solution in the industry. PacificGMP partners with drug developers by providing a range of cGMP and non-GMP services from cell line optimization, early process design, development and scale-up, to preclinical, clinical manufacturing, aseptic filling, testing, analytical services and regulatory support. More information can be found by visiting the Company's web site at www.PacificGMP.com.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. is engaged in the development and commercialization of alpha particle immunotherapeutics based on its unique patent position for the utilization of actinium-225 and bismuth-213. It has facilities in Florham Park, New Jersey and Oak Ridge, Tennessee. More information can be found by visiting the Company's web site at www.actiniumpharmaceuticals.com

    Contact:

    PacificGMP
    Gary Pierce
    Chief Business Officer
    858-550-4094

Available Topic Expert(s): For information on the listed expert(s), click
appropriate link.
Leigh Pierce
http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=67271


'/>"/>
SOURCE PacificGMP
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. PacificGMP Announces Agreement with BD Biosciences for Cell Banking and cGMP Antibody Manufacturing
2. PacificGMP to Merge With Pacific Biopharma Group and Create Innovative US-Compliant cGMP Contract Biomanufacturing Facility in China
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... LabRoots , the leading provider ... the world, is pleased to announce the launch of a new scholarship for young ... fields. , This merit-based scholarship is open to all high school seniors, 17 years ...
(Date:2/22/2017)... 22, 2017 Aethlon Medical, Inc. (Nasdaq: ... study that validated the ability of the Aethlon Hemopurifier® ... increased mortality in immune-suppressed sepsis patients and also contribute ... The objective of the study was to validate the ... virus (EBV) and Herpes Simplex virus 1 (HSV1) by ...
(Date:2/22/2017)... and SAN DIEGO , Feb. ... "Company") (OTCQB:CELZ) announced today expansion of its translational ... cell product through establishment of laboratory facilities in ... at the San Diego BioLabs facility, a biotechnology ... Novartis, and Sanofi. In November 2016, ...
(Date:2/21/2017)... , Feb. 21, 2017 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" ... and operational results for the three months ended December 31, ... -based life sciences and diagnostics company that develops and ... ... continue to build on the commercial milestones achieved in fiscal ...
Breaking Biology Technology:
(Date:1/24/2017)... , Jan. 24, 2017 Biopharm ... of the laboratory use of nuclear magnetic resonance ... experienced end-users and profiled current practices, developments, trends ... as well as growth and opportunities. These areas ... suppliers, NMR instruments, needs and innovation requirements, hyphenated ...
(Date:1/21/2017)... Research and Markets has announced the addition ... to their offering. ... The global voice recognition biometrics market to grow at a ... report covers the present scenario and the growth prospects of the ... size, the report considers the revenue generated from the sales of ...
(Date:1/18/2017)...  In vitro diagnostic (IVD) companies were very active ... and Kalorama Information expects that trend to continue – ... Generally, uncertainty in reimbursement and healthcare reform in ... the acquisitions landscape. Instead of looking to buy technology, ... outside of their home country and also to increase ...
Breaking Biology News(10 mins):